Between 2017 and 2023, nearly 250,000 cancer cases were reported in the country, highlighting a concerning rise in both incidence and mortality rates. Among the various types of cancer, breast, colorectal, lung, lymphoma, and liver cancer emerged as the most prevalent, underscoring the need for increased awareness, early detection, and improved treatment strategies.
Health Minister Datuk Seri Dr. Dzulkefly Ahmad revealed that cancer accounted for 14 percent of deaths in 2023, an increase from 13 percent the previous year, making it the third leading cause of death in the country.
However, he emphasized that despite these concerning figures, there is hope. This hope, he stated, relies on collective efforts to strengthen prevention, promote early screening, and improve access to treatment. He reiterated that these initiatives remain a key priority for the Ministry of Health in its efforts to reform the nation’s healthcare system.
He made these remarks while officiating the National World Cancer Day 2025 celebration, held under the theme “Unity in Uniqueness.”
Additionally, Dzulkefly announced that Malaysia, in collaboration with the World Health Organization (WHO) and 14 other member states, will introduce the Lung Health Resolution at this year’s World Health Assembly (WHA). He stated that this initiative is part of Malaysia’s efforts to position lung health as a key priority on the global health agenda while also promoting greater investment in lung cancer screening and treatment.
Last year, Malaysia played a pivotal role in tackling the global impact of lung diseases by leading the historic submission of the WHO Lung Health Resolution at the World Cancer Congress in Geneva, Switzerland.
The resolution, set to be adopted as a global health priority at the World Health Assembly (WHA) and the United Nations General Assembly (UNGA) this year, aims to elevate lung health on international platforms and drive meaningful action.
During the celebration, Dzulkefly also observed the signing of a Memorandum of Understanding (MoU) for the Lung Health Initiative Malaysia. The agreement brought together eight strategic partners, including the National Cancer Society Malaysia (NCSM), Malaysia Industrial Safety and Health Association (MiSHA), Malaysian Drug Prevention Association (PEMADAM), Translab (M) Sdn Bhd, JNTL (Malaysia) Sdn Bhd, AstraZeneca Sdn Bhd, Johnson & Johnson Sdn Bhd, and Axios International Sdn Bhd. This collaboration aims to strengthen efforts in promoting lung health and enhancing disease prevention initiatives in the country.
The increasing prevalence of cancer in Malaysia highlights the urgent need for enhanced awareness, early detection, and improved treatment strategies. As the government and healthcare organizations intensify their efforts to combat this rising health crisis, initiatives like the Lung Health Resolution and strategic partnerships through the Lung Health Initiative Malaysia mark significant steps toward better prevention and care. With continued collaboration, investment, and public engagement, Malaysia aims to strengthen its healthcare system and improve outcomes for those affected by cancer.
Source: Malay Mail
